by admin | Dec 20, 2021 | press-releases
Home PRESS RELEASE CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy Study of cretostimogene grenadenorepvecin Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin 💻 DESKTOP AUDIO PLAYER ===============================...
by admin | Nov 13, 2021 | press-releases
Home PRESS RELEASE CG Oncology Presents Preliminary Phase 2 Data with cretostimogene grenadenorepvec in Combination with pembrolizumab in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin 💻 DESKTOP AUDIO PLAYER ===============================...
by admin | Oct 12, 2021 | press-releases
Home PRESS RELEASE CG Oncology to Present Two Programs at The Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER...
by admin | Sep 22, 2021 | press-releases
Home PRESS RELEASE CG Oncology and Roche to Collaborate on Clinical Trial of Oncolytic Immunotherapy cretostimogene grenadenorepvec as Part of Novel Combination for Various Solid Tumor Indications 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to...
by admin | Sep 9, 2021 | press-releases
Home PRESS RELEASE CG Oncology Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Oncolytic Immunotherapy cretostimogene grenadenorepvec in Combination with nivolumab in Metastatic Urothelial Cancer 💻 DESKTOP AUDIO PLAYER...
by admin | Dec 10, 2020 | press-releases
Home PRESS RELEASE CG Oncology Closes $47 Million Series D Financing 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER =============================== --> Listen to this article now 0:00 0.5x 0.75x Normal...